Clinical Trial Update: A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of MK-1029 in adults with persistent asthma was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• MK-1029

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Asthma | Phase 2 | Status: TERMINATED | Results posted: 2018-09-13